Patricia Alves and Jaclyn Fonteyne: TweetChat Return on Investment
In this 2.5-minute audio snippet, Patricia Alves and Jaclyn Fonteyne, members of the Boehringer Ingelheim Social Media Team, talk about the working with legal-regulatory to plan TweetChats and what they consider to be the measures of success -- aka, return on investment -- for pharma TweetChats.
Jeff Tangney: How Doximity Creates Online Physician “Niche” Communities & Discussions
In this 2-minute audio snippet, Jeff Tangney, CEO & Founder, Doximity, talks about online physician chat rooms and how 'niche' communities are created around specific content posted to the site.
Five Minute or Less Audio Interviews
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy™ Interviews John LaMattina: Devalued and Distrusted
In this 4-minute snippet, recorded 28 May 2013, John LaMattina, former Pfizer president of Research and Development, reveals what inspired him to write the book "Devalued and Distrusted: Can the Pharmaceutical Industry restore Its Broken Image?"
Pharmaguy Featured in Videos
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy™’s Twitter Stream – Q4 2009
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Big Pharma Racks Up Facebook Likes But Not So Much from Patients
In this 2.5-minute audio snippet, Pharmaguy contemplates how big drug companies can get hundreds of thousands of 'likes' on Facebook but score very low among patient groups worldwide. Only 25% of patients, for example, think pharma marketing is ethical. A case in point is Low-T direct-to-consumer advertising.
Pharmaguy™’s Twitter Stream – Q4 2011
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Reports of the Demise of Medical Journal Ads Have Been Greatly Exaggerated
In this 2.5-minute audio snippet, Pharmaguy presents data from Kantar Media that shows that the death of professional print pharma advertising has been greatly exaggerated. He gets into which companies and drugs have spent the most on journal advertising and summarizes a study of physician attitudes regarding these ads.
Todd D. Clark: What Can Pharma Do to Avoid the Slow-Growth Trap?
In this 3-minute audio snippet, Todd D. Clark, President of Value of Insight Consulting and the author of pharmahandbook and generichandbook, discusses a few ideas on how the pharmaceutical industry can avoid the slow-growth trap in the U.S. market.
